Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE M 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE M 200.
ISOVUE-128 vs ISOVUE-M 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.
Adult: 50-200 mL (0.5-2.0 mL/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Intrathecal: 8-12 mL (200 mg Iodine/mL) for lumbar myelography. Intravenous: 50-200 mL for contrast enhancement, administered as a bolus or infusion per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 mL/min).
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. Prolonged in renal impairment, which may necessitate dose adjustment.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Primarily renal: >90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 1% is excreted via biliary/fecal routes.
Category C
Category C
Contrast Media
Contrast Media